* Brickell Biotech Inc BBI.OQ BBI.O is expected to show
a rise
in quarterly revenue when it reports results on March 7
(estimated).
* The Boulder Colorado-based company is expected to report
a
458.0% increase in revenue to $150.67 thousand from $27 thousand
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Brickell Biotech
Inc is
for a loss of 10 cents per share. For the same quarter last
year, the company reported a loss of 15 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Brickell
Biotech
Inc is $4, about 94.6% above its last closing price
of $0.21.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.12 -0.16 Missed -28
Jun. 30 2021 -0.14 -0.12 -0.16 Missed -28
Mar. 31 2021 -0.11 -0.11 -0.15 Missed -30.4
Dec. 31 2020 -0.09 -0.09 -0.15 Missed -66.7
Sep. -0.19 -0.18 -0.15 Beat 18.9
30 2020
-1.37
This summary was machine generated March 4 at 22:19 GMT. All
figures in US dollars unless otherwise stated